Concert Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals

Lexington, mass.--(business wire)---- $cnce #alopeciaareata--concert maintains deuruxolitinib breakthrough therapy designation from fda for the treatment of alopecia areata.

New york--(business wire)--halper sadeh llc, an investor rights law firm, is investigating whether the sale of concert pharmaceuticals, inc. (nasdaq: cnce) to sun pharmaceutical industries limited is fair to concert shareholders. per the terms of the agreement, sun pharma would acquire concert for an upfront payment of $8.00 per share in cash, plus a non-tradeable contingent value right entitling concert shareholders to receive up to an additional $3.50 per share in cash, payable upon deuruxolitinib achieving certain net sales milestones within specified periods. halper sadeh encourages concert shareholders to click here to learn more about their legal rights and options or contact daniel sadeh or zachary halper at (212) 763-0060 or sadeh@halpersadeh...

New york , jan. 30, 2023 /prnewswire/ -- if you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: joshua rubin, esq. weiss law 305 broadway, 7th floor  new york, ny 10007 (212) 682-3025  (888) 593-4771 stockinfo@weisslawllp.com evoqua water technologies corp. (nyse: aqua) weiss law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of evoqua water technologies corp. (nyse: aqua) in connection with the proposed acquisition of aqua by xylem inc. ("xylem").

New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of concert pharmaceuticals, inc. (nasdaqgm: cnce) to sun pharmaceutical industries limited. under the terms of the proposed transaction, shareholders of concert will receive $8.00 in cash plus one contingent value right (cvr) (entitling its holder to receive up to an additional $3.50 per share of common stock in cash upon achieving certain net sales milestones) for each share of concert that they own. ksf is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the company...

New york , jan. 19, 2023 /prnewswire/ -- weiss law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of concert pharmaceuticals, inc. ("concert" or the "company") (nasdaq: cnce), in connection with the proposed acquisition of the company by sun pharmaceutical industries limited via tender offer. under the terms of the merger agreement, the company's shareholders will receive $8.00 in cash for each share of concert common stock owned, plus one non-tradeable contingent value right ("cvr") per share.

Concert Pharmaceuticals, Inc. is a biotech buyout trading at a negative spread but with an interesting CVR attached. The CVR is based on two sales milestones.

Concert Pharmaceuticals (CNCE) enters into a definitive agreement to be acquired by India-based Sun Pharmaceutical for $576 million. Stock up 17% in the previous week.

The company is changing hands in a deal worth at least $576 million.

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE ) Q3 2022 Earnings Conference Call November 7, 2022 8:30 AM ET Company Participants Justine Koenigsberg - Senior Vice President, Corporate Communications and Investor Relation Roger Tung - President and Chief Executive Officer Marc Becker - Chief Financial Officer James Cassella - Chief Development Officer Nancy Stuart - Chief Operating Officer Conference Call Participants Maury Raycroft - Jefferies Leszek Sulewski - Truist Sean Kim - JonesTrading Jason Butler - JMP Securities Operator Good day and thank you for standing by. And welcome to Concert Pharmaceuticals Third Quarter 2022 Investor Call.

Concert (CNCE) delivered earnings and revenue surprises of 1.69% and 97.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

LEXINGTON, Mass.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Concert (CNCE) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

The average of price targets set by Wall Street analysts indicates a potential upside of 126.6% in Concert (CNCE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Concert (CNCE) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Does Concert Pharmaceuticals (CNCE) have what it takes to be a top stock pick for momentum investors? Let's find out.